This page has only limited features, please log in for full access.
Long-term enteral nutrition (LTEN) can induce gut microbiota (GM) dysbiosis and gastrointestinal related symptoms, such as constipation or diarrhoea. To date, the treatment of constipation is based on the use of laxatives and prebiotics. Only recently have probiotics and synbiotics been considered, the latter modulating the GM and regulating intestinal functions. This randomized open-label intervention study evaluated the effects of synbiotic treatment on the GM profile, its functional activity and on intestinal functions in long-term home EN (LTHEN) patients. Twenty LTHEN patients were recruited to take enteral formula plus one sachet/day of synbiotic (intervention group, IG) or enteral formula (control group, CG) for four months and evaluated for constipation, stool consistency, and GM and metabolite profiles. In IG patients, statistically significant reduction of constipation and increase of stool consistency were observed after four months (T1), compared to CG subjects. GM ecology analyses revealed a decrease in the microbial diversity of both IC and CG groups. Biodiversity increased at T1 for 5/11 IG patients and Methanobrevibacter was identified as the biomarker correlated to the richness increase. Moreover, the increase of short chain fatty acids and the reduction of harmful molecules have been correlated to synbiotic administration. Synbiotics improve constipation symptoms and influences Methanobrevibacter growth in LTHEN patients.
Valentina D’Onofrio; Federica Del Chierico; Paola Belci; Pamela Vernocchi; Andrea Quagliariello; Sofia Reddel; Giorgia Conta; Maria Vittoria Mancino; Maurizio Fadda; Maria Carmine Scigliano; Roberta Morelli; Antonella De Francesco; Fabio Guagnini; Filippo Fassio; Rosalba Galletti; Lorenza Putignani. Effects of a Synbiotic Formula on Functional Bowel Disorders and Gut Microbiota Profile during Long-Term Home Enteral Nutrition (LTHEN): A Pilot Study. Nutrients 2020, 13, 87 .
AMA StyleValentina D’Onofrio, Federica Del Chierico, Paola Belci, Pamela Vernocchi, Andrea Quagliariello, Sofia Reddel, Giorgia Conta, Maria Vittoria Mancino, Maurizio Fadda, Maria Carmine Scigliano, Roberta Morelli, Antonella De Francesco, Fabio Guagnini, Filippo Fassio, Rosalba Galletti, Lorenza Putignani. Effects of a Synbiotic Formula on Functional Bowel Disorders and Gut Microbiota Profile during Long-Term Home Enteral Nutrition (LTHEN): A Pilot Study. Nutrients. 2020; 13 (1):87.
Chicago/Turabian StyleValentina D’Onofrio; Federica Del Chierico; Paola Belci; Pamela Vernocchi; Andrea Quagliariello; Sofia Reddel; Giorgia Conta; Maria Vittoria Mancino; Maurizio Fadda; Maria Carmine Scigliano; Roberta Morelli; Antonella De Francesco; Fabio Guagnini; Filippo Fassio; Rosalba Galletti; Lorenza Putignani. 2020. "Effects of a Synbiotic Formula on Functional Bowel Disorders and Gut Microbiota Profile during Long-Term Home Enteral Nutrition (LTHEN): A Pilot Study." Nutrients 13, no. 1: 87.
Background Urticaria is a disorder affecting skin and mucosal tissues characterized by the occurrence of wheals, angioedema or both, the latter defining the urticaria-angioedema syndrome. It is estimated that 12–22% of the general population has suffered at least one subtype of urticaria during life, but only a small percentage (estimated at 7.6–16%) has acute urticaria, because it is usually self-limited and resolves spontaneously without requiring medical attention. This makes likely that its incidence is underestimated. The epidemiological data currently available on chronic urticaria in many cases are deeply discordant and not univocal, but a recent Italian study, based on the consultation of a national registry, reports a prevalence of chronic spontaneous urticaria of 0.02% to 0.4% and an incidence of 0.1–1.5 cases/1000 inhabitants/year. Methods We reviewed the recent international guidelines about urticaria and we described a methodologic approach based on classification, pathophysiology, impact on quality of life, diagnosis and prognosis, differential diagnosis and management of all the types of urticaria. Conclusions The aim of the present document from the Italian Society of Allergology, Asthma and Clinical Immunology (SIAAIC) and the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA) is to provide updated information to all physicians involved in diagnosis and management of urticaria and angioedema.
Eustachio Nettis; Caterina Foti; Marina Ambrifi; Ilaria Baiardini; Leonardo Bianchi; Alessandro Borghi; Marco Caminati; Giorgio Walter Canonica; Marco Casciaro; Laura Colli; Giselda Colombo; Monica Corazza; Antonio Cristaudo; Giulia De Feo; Ornella De Pita’; Mario Di Gioacchino; Elisabetta Di Leo; Filippo Fassio; Sebastiano Gangemi; Alessia Gatta; Katharina Hansel; Enrico Heffler; Cristoforo Incorvaia; Maddalena Napolitano; Cataldo Patruno; Silvia Peveri; Paolo Daniele Pigatto; Cristina Quecchia; Anna Radice; Giuseppe Alvise Ramirez; Paolo Romita; Franco Rongioletti; Oliviero Rossi; Eleonora Savi; Gianenrico Senna; Massimo Triggiani; Myriam Zucca; Enrico Maggi; Luca Stingeni. Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology. Clinical and Molecular Allergy 2020, 18, 1 -19.
AMA StyleEustachio Nettis, Caterina Foti, Marina Ambrifi, Ilaria Baiardini, Leonardo Bianchi, Alessandro Borghi, Marco Caminati, Giorgio Walter Canonica, Marco Casciaro, Laura Colli, Giselda Colombo, Monica Corazza, Antonio Cristaudo, Giulia De Feo, Ornella De Pita’, Mario Di Gioacchino, Elisabetta Di Leo, Filippo Fassio, Sebastiano Gangemi, Alessia Gatta, Katharina Hansel, Enrico Heffler, Cristoforo Incorvaia, Maddalena Napolitano, Cataldo Patruno, Silvia Peveri, Paolo Daniele Pigatto, Cristina Quecchia, Anna Radice, Giuseppe Alvise Ramirez, Paolo Romita, Franco Rongioletti, Oliviero Rossi, Eleonora Savi, Gianenrico Senna, Massimo Triggiani, Myriam Zucca, Enrico Maggi, Luca Stingeni. Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology. Clinical and Molecular Allergy. 2020; 18 (1):1-19.
Chicago/Turabian StyleEustachio Nettis; Caterina Foti; Marina Ambrifi; Ilaria Baiardini; Leonardo Bianchi; Alessandro Borghi; Marco Caminati; Giorgio Walter Canonica; Marco Casciaro; Laura Colli; Giselda Colombo; Monica Corazza; Antonio Cristaudo; Giulia De Feo; Ornella De Pita’; Mario Di Gioacchino; Elisabetta Di Leo; Filippo Fassio; Sebastiano Gangemi; Alessia Gatta; Katharina Hansel; Enrico Heffler; Cristoforo Incorvaia; Maddalena Napolitano; Cataldo Patruno; Silvia Peveri; Paolo Daniele Pigatto; Cristina Quecchia; Anna Radice; Giuseppe Alvise Ramirez; Paolo Romita; Franco Rongioletti; Oliviero Rossi; Eleonora Savi; Gianenrico Senna; Massimo Triggiani; Myriam Zucca; Enrico Maggi; Luca Stingeni. 2020. "Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology." Clinical and Molecular Allergy 18, no. 1: 1-19.
Milk is a fundamental component of the diet of every mammal; nevertheless, not every individual can tolerate this kind of food, especially in adulthood. However, lactose intolerance has only been recognized in the last 50 years, and currently, lactose intolerance is defined as a clinical syndrome characterized by pain, abdominal distention, flatulence, and diarrhoea that occur after lactose consumption. Lactose is currently a common disaccharide in human nutrition, both in breastfed infants and in adults, but its digestion requires a specialized enzyme called lactase. The genetically programmed reduction in lactase activity during adulthood affects most of the world’s adult population and can cause troublesome digestive symptoms, which may also vary depending on the amount of residual lactase activity; the small bowel transit time; and, especially, the amount of ingested lactose. Several diagnostic tests are currently available for lactose intolerance, but the diagnosis remains challenging. The treatment for lactose intolerance mainly consists of reducing or eliminating the dietetic amount of lactose until the symptoms disappear, but this is hard to achieve, as lactose is present in dairy products and is even commonly used as a food additive. In addition to dietetic restriction of lactose-containing foods, lactase can be administered as an enzymatic food supplement, but its efficacy is still controversial. Recently, probiotics have been proposed for the management of lactose intolerance; certain probiotic strains have shown specific β-galactosidase activity, thus aiding in the digestion of lactose. The aim of this paper was to review the current knowledge about lactose intolerance and to discuss the potential for the use of specific probiotic strains such as dietary supplements in lactose-intolerant patients.
Filippo Fassio; Maria Sole Facioni; Fabio Guagnini. Lactose Maldigestion, Malabsorption, and Intolerance: A Comprehensive Review with a Focus on Current Management and Future Perspectives. Nutrients 2018, 10, 1599 .
AMA StyleFilippo Fassio, Maria Sole Facioni, Fabio Guagnini. Lactose Maldigestion, Malabsorption, and Intolerance: A Comprehensive Review with a Focus on Current Management and Future Perspectives. Nutrients. 2018; 10 (11):1599.
Chicago/Turabian StyleFilippo Fassio; Maria Sole Facioni; Fabio Guagnini. 2018. "Lactose Maldigestion, Malabsorption, and Intolerance: A Comprehensive Review with a Focus on Current Management and Future Perspectives." Nutrients 10, no. 11: 1599.
The socio-economic burden of allergic respiratory conditions on continental Europe is even higher than that of mainstream diseases, such as diabetes and cardiovascular disease, as allergic rhinitis alone accounts for billions of Euros in healthcare expenses across Europe. House dust mites (HDM) are one of the most common triggers behind allergic rhinitis and asthma. The role of probiotics in the treatment and prevention of some allergic conditions, such as atopic dermatitis, is already well recognized, whereas evidence about their efficacy in patients with respiratory allergies—while increasing—is still limited. Here the current evidence for the use of probiotics in patients with allergic rhinitis and/or asthma is discussed.
Filippo Fassio; Fabio Guagnini. House dust mite-related respiratory allergies and probiotics: a narrative review. Clinical and Molecular Allergy 2018, 16, 15 .
AMA StyleFilippo Fassio, Fabio Guagnini. House dust mite-related respiratory allergies and probiotics: a narrative review. Clinical and Molecular Allergy. 2018; 16 (1):15.
Chicago/Turabian StyleFilippo Fassio; Fabio Guagnini. 2018. "House dust mite-related respiratory allergies and probiotics: a narrative review." Clinical and Molecular Allergy 16, no. 1: 15.
Francesco Liotta; Francesco Annunziato; Sergio Castellani; Maria Boddi; Brunetto Alterini; Giovanni Castellini; Benedetta Mazzanti; Lorenzo Cosmi; Manlio Acquafresca; Filippo Bartalesi; Beatrice Dilaghi; Walter Dorigo; Gabriele Graziani; Benedetta Bartolozzi; Guido Bellandi; Giulia Carli; Alessandro Bartoloni; Aaron Thomas Fargion; Filippo Fassio; Paolo Fontanari; Giancarlo Landini; Eleonora A.M. Lucente; Stefano Michelagnoli; Carolina Orsi Battaglini; Grazia Panigada; Clara Pigozzi; Valentina Querci; Veronica Santarlasci; Paola Parronchi; Nicola Troisi; Cristiana Baggiore; Paola Romagnani; Edoardo Mannucci; Riccardo Saccardi; Carlo Pratesi; Gianfranco Gensini; Sergio Romagnani; Enrico Maggi. Therapeutic Efficacy of Autologous Non-Mobilized Enriched Circulating Endothelial Progenitors in Patients With Critical Limb Ischemia ― The SCELTA Trial ―. Circulation Journal 2018, 82, 1688 -1698.
AMA StyleFrancesco Liotta, Francesco Annunziato, Sergio Castellani, Maria Boddi, Brunetto Alterini, Giovanni Castellini, Benedetta Mazzanti, Lorenzo Cosmi, Manlio Acquafresca, Filippo Bartalesi, Beatrice Dilaghi, Walter Dorigo, Gabriele Graziani, Benedetta Bartolozzi, Guido Bellandi, Giulia Carli, Alessandro Bartoloni, Aaron Thomas Fargion, Filippo Fassio, Paolo Fontanari, Giancarlo Landini, Eleonora A.M. Lucente, Stefano Michelagnoli, Carolina Orsi Battaglini, Grazia Panigada, Clara Pigozzi, Valentina Querci, Veronica Santarlasci, Paola Parronchi, Nicola Troisi, Cristiana Baggiore, Paola Romagnani, Edoardo Mannucci, Riccardo Saccardi, Carlo Pratesi, Gianfranco Gensini, Sergio Romagnani, Enrico Maggi. Therapeutic Efficacy of Autologous Non-Mobilized Enriched Circulating Endothelial Progenitors in Patients With Critical Limb Ischemia ― The SCELTA Trial ―. Circulation Journal. 2018; 82 (6):1688-1698.
Chicago/Turabian StyleFrancesco Liotta; Francesco Annunziato; Sergio Castellani; Maria Boddi; Brunetto Alterini; Giovanni Castellini; Benedetta Mazzanti; Lorenzo Cosmi; Manlio Acquafresca; Filippo Bartalesi; Beatrice Dilaghi; Walter Dorigo; Gabriele Graziani; Benedetta Bartolozzi; Guido Bellandi; Giulia Carli; Alessandro Bartoloni; Aaron Thomas Fargion; Filippo Fassio; Paolo Fontanari; Giancarlo Landini; Eleonora A.M. Lucente; Stefano Michelagnoli; Carolina Orsi Battaglini; Grazia Panigada; Clara Pigozzi; Valentina Querci; Veronica Santarlasci; Paola Parronchi; Nicola Troisi; Cristiana Baggiore; Paola Romagnani; Edoardo Mannucci; Riccardo Saccardi; Carlo Pratesi; Gianfranco Gensini; Sergio Romagnani; Enrico Maggi. 2018. "Therapeutic Efficacy of Autologous Non-Mobilized Enriched Circulating Endothelial Progenitors in Patients With Critical Limb Ischemia ― The SCELTA Trial ―." Circulation Journal 82, no. 6: 1688-1698.
IgE sensitization tests, such as skin prick testing and serum specific IgE, have been used to diagnose IgE-mediated clinical allergy for many years. Their prime drawback is that they detect sensitization which is only loosely related to clinical allergy. Many patients therefore require provocation tests to make a definitive diagnosis; these are often expensive and potentially associated with severe reactions. The likelihood of clinical allergy can be semi-quantified from an IgE sensitization test results. This relationship varies though according to the patients’ age, ethnicity, nature of the putative allergic reaction and co-existing clinical diseases such as eczema. The likelihood of clinical allergy can be more precisely estimated from an IgE sensitization test result, by taking into account the patient's presenting features (pre-test probability). The presence of each of these patient specific factors may mean that a patient is more or less likely to have clinically allergy with a given test result (post-test probability). We present two approaches to including pre-test probabilities in the interpretation of results. These approaches are currently limited by a lack of data to allow us to derive pre-test probabilities for diverse setting, regions and allergens. Also, co-factors, such as exercise, may be necessary for exposure to an allergen to result in an allergic reaction in specific IgE positive patients. The diagnosis of IgE-mediated allergy is now being aided by the introduction of allergen component testing which may identify clinically relevant sensitization. Other approaches are in development with basophil activation testing being closest to clinical application.This article is protected by copyright. All rights reserved.
Graham Roberts; Markus Ollert; Rob Aalberse; Moira Austin; Adnan Custovic; Audrey DunnGalvin; Philippe A Eigenmann; Filippo Fassio; Clive Grattan; Peter Hellings; Jonathan Hourihane; Edward Knol; Antonella Muraro; Nikolaos Papadopoulos; Alexandra F. Santos; Sabine Schnadt; Kassiani Tzeli. A new framework for the interpretation of IgE sensitization tests. Allergy 2016, 71, 1540 -1551.
AMA StyleGraham Roberts, Markus Ollert, Rob Aalberse, Moira Austin, Adnan Custovic, Audrey DunnGalvin, Philippe A Eigenmann, Filippo Fassio, Clive Grattan, Peter Hellings, Jonathan Hourihane, Edward Knol, Antonella Muraro, Nikolaos Papadopoulos, Alexandra F. Santos, Sabine Schnadt, Kassiani Tzeli. A new framework for the interpretation of IgE sensitization tests. Allergy. 2016; 71 (11):1540-1551.
Chicago/Turabian StyleGraham Roberts; Markus Ollert; Rob Aalberse; Moira Austin; Adnan Custovic; Audrey DunnGalvin; Philippe A Eigenmann; Filippo Fassio; Clive Grattan; Peter Hellings; Jonathan Hourihane; Edward Knol; Antonella Muraro; Nikolaos Papadopoulos; Alexandra F. Santos; Sabine Schnadt; Kassiani Tzeli. 2016. "A new framework for the interpretation of IgE sensitization tests." Allergy 71, no. 11: 1540-1551.
Kounis syndrome is defined as the co-incidental occurrence of an acute coronary syndrome with hypersensitivity reactions following an allergenic event and was first described by Kounis and Zavras in 1991 as an allergic angina syndrome. Multiple causes have been described and most of the data in the literature are derived from the description of clinical cases - mostly in adult patients - and the pathophysiology remains only partly explained. Three different variants of Kounis syndrome have been defined: type I (without coronary disease) is defined as chest pain during an acute allergic reaction in patients without risk factors or coronary lesions in which the allergic event induces coronary spasm that electrocardiographic changes secondary to ischemia; type II (with coronary disease) includes patients with pre-existing atheromatous disease, either previously quiescent or symptomatic, in whom acute hypersensitive reactions cause plaque erosion or rupture, culminating in acute myocardial infarction; more recently a type-III variant of Kounis syndrome has been defined in patients with preexisting coronary disease and drug eluting coronary stent thrombosis. The pathogenesis of the syndrome is discussed, and a therapeutic algorithm is proposed.
Filippo Fassio; Laura Losappio; Dario Antolin-Amerigo; Silvia Peveri; Gianni Pala; Donatella Preziosi; Ilaria Massaro; Gabriele Giuliani; Chiara Gasperini; Marco Caminati; Enrico Heffler. Kounis syndrome: A concise review with focus on management. European Journal of Internal Medicine 2016, 30, 7 -10.
AMA StyleFilippo Fassio, Laura Losappio, Dario Antolin-Amerigo, Silvia Peveri, Gianni Pala, Donatella Preziosi, Ilaria Massaro, Gabriele Giuliani, Chiara Gasperini, Marco Caminati, Enrico Heffler. Kounis syndrome: A concise review with focus on management. European Journal of Internal Medicine. 2016; 30 ():7-10.
Chicago/Turabian StyleFilippo Fassio; Laura Losappio; Dario Antolin-Amerigo; Silvia Peveri; Gianni Pala; Donatella Preziosi; Ilaria Massaro; Gabriele Giuliani; Chiara Gasperini; Marco Caminati; Enrico Heffler. 2016. "Kounis syndrome: A concise review with focus on management." European Journal of Internal Medicine 30, no. : 7-10.
We thank Kounis and coll. for their Letter to the Editor [1] commenting and congratulating for our recently published article “Kounis syndrome: A concise review with focus on management” [2].
Enrico Heffler; Filippo Fassio. Author's reply: Kounis syndrome: Aspects on pathophysiology and management. European Journal of Internal Medicine 2016, 32, e32 .
AMA StyleEnrico Heffler, Filippo Fassio. Author's reply: Kounis syndrome: Aspects on pathophysiology and management. European Journal of Internal Medicine. 2016; 32 ():e32.
Chicago/Turabian StyleEnrico Heffler; Filippo Fassio. 2016. "Author's reply: Kounis syndrome: Aspects on pathophysiology and management." European Journal of Internal Medicine 32, no. : e32.
Rhinitis is often the first symptom of allergy but is frequently ignored and classified as a nuisance condition. Ironically it has the greatest socioeconomic burden worldwide caused by its impact on work and on daily life. However, patients appear reticent to seek professional advice, visiting their doctor only when symptoms become 'intolerable' and often when their usual therapy proves ineffective. Clearly, it's time for new and more effective allergic rhinitis treatments. MP29-02 (Dymista®; Meda, Solna, Sweden) is a new class of medication for moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or intranasal corticosteroids is not considered sufficient. MP29-02 is a novel formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP). It benefits not only from the incorporation of two active agents, but also from a novel formulation; its lower viscosity, smaller droplet size, larger volume (137 μl) and wider spray angle ensure optimal coverage of, and retention on the nasal mucosa and contribute to its clinical efficacy. In clinical trials, patients treated with MP29-02 experienced twice the symptom relief as those treated with FP and AZE, who in turn exhibited significantly greater symptom relief than placebo-patients. Indeed, the advantage of MP29-02 over FP was approximately the same as that shown for FP over placebo. The advantage of MP29-02 was particularly evident in those patients for whom nasal congestion is predominant, with MP29-02 providing three times the nasal congestion relief of FP (p = 0.0018) and five times the relief of AZE (p = 0.0001). Moreover, patients treated with MP29-02 achieved each and every response up to a week faster than those treated with FP or AZE alone and in real life 1 in 2 patients reported the perception of well-controlled disease after only 3 days. MP29-02's superiority over FP was also apparent long-term in patients with perennial allergic rhinitis or non-allergic rhinitis, with statistical significance noted from the first day of treatment, with treatment difference maintained for a full year. Taken together, these data suggest that MP29-02 may improve the lives of many of our patients, enabling them to finally escape the allergic rhinitis trap.
Oliviero Rossi; Ilaria Massaro; Marco Caminati; Cristina Quecchia; Filippo Fassio; Enrico Heffler; Giorgio Walter Canonica. Escaping the trap of allergic rhinitis. Clinical and Molecular Allergy 2015, 13, 17 .
AMA StyleOliviero Rossi, Ilaria Massaro, Marco Caminati, Cristina Quecchia, Filippo Fassio, Enrico Heffler, Giorgio Walter Canonica. Escaping the trap of allergic rhinitis. Clinical and Molecular Allergy. 2015; 13 (1):17.
Chicago/Turabian StyleOliviero Rossi; Ilaria Massaro; Marco Caminati; Cristina Quecchia; Filippo Fassio; Enrico Heffler; Giorgio Walter Canonica. 2015. "Escaping the trap of allergic rhinitis." Clinical and Molecular Allergy 13, no. 1: 17.
Erminia Ridolo; Marcello Montagni; Filippo Fassio; Ilaria Massaro; Oliviero Rossi; Cristoforo Incorvaia; Giorgio Walter Canonica. Rupatadine for the treatment of allergic rhinitis and urticaria: a look at the clinical data. Clinical Investigation 2014, 4, 453 -461.
AMA StyleErminia Ridolo, Marcello Montagni, Filippo Fassio, Ilaria Massaro, Oliviero Rossi, Cristoforo Incorvaia, Giorgio Walter Canonica. Rupatadine for the treatment of allergic rhinitis and urticaria: a look at the clinical data. Clinical Investigation. 2014; 4 (5):453-461.
Chicago/Turabian StyleErminia Ridolo; Marcello Montagni; Filippo Fassio; Ilaria Massaro; Oliviero Rossi; Cristoforo Incorvaia; Giorgio Walter Canonica. 2014. "Rupatadine for the treatment of allergic rhinitis and urticaria: a look at the clinical data." Clinical Investigation 4, no. 5: 453-461.
Filippo Fassio; Fabio Almerigogna. Comment on herpes simplex encephalitis with occipital localization in an infant: a different route of entry in the brain system? Pediatric Neurology 2014, 50, e7 -8.
AMA StyleFilippo Fassio, Fabio Almerigogna. Comment on herpes simplex encephalitis with occipital localization in an infant: a different route of entry in the brain system? Pediatric Neurology. 2014; 50 (3):e7-8.
Chicago/Turabian StyleFilippo Fassio; Fabio Almerigogna. 2014. "Comment on herpes simplex encephalitis with occipital localization in an infant: a different route of entry in the brain system?" Pediatric Neurology 50, no. 3: e7-8.
Giuseppina Manzotti; Enrico Heffler; Filippo Fassio. Probiotics as a Novel Adjuvant Approach to Atopic Dermatitis. Journal of Contemporary Immunology 2014, 1 .
AMA StyleGiuseppina Manzotti, Enrico Heffler, Filippo Fassio. Probiotics as a Novel Adjuvant Approach to Atopic Dermatitis. Journal of Contemporary Immunology. 2014; ():1.
Chicago/Turabian StyleGiuseppina Manzotti; Enrico Heffler; Filippo Fassio. 2014. "Probiotics as a Novel Adjuvant Approach to Atopic Dermatitis." Journal of Contemporary Immunology , no. : 1.
Giuseppina Manzotti; Enrico Heffler; Filippo Fassio. Multi-strain Symbiotic Preparations as a Novel Adjuvant Approach to Allergic Rhinitis. Journal of Contemporary Immunology 2014, 1 .
AMA StyleGiuseppina Manzotti, Enrico Heffler, Filippo Fassio. Multi-strain Symbiotic Preparations as a Novel Adjuvant Approach to Allergic Rhinitis. Journal of Contemporary Immunology. 2014; ():1.
Chicago/Turabian StyleGiuseppina Manzotti; Enrico Heffler; Filippo Fassio. 2014. "Multi-strain Symbiotic Preparations as a Novel Adjuvant Approach to Allergic Rhinitis." Journal of Contemporary Immunology , no. : 1.
R.G. Romanelli; F. Fassio; F. Cappelli; M.G. Giudizi; I. Cecioni; A. Matucci; F. Castiglione; R. Tarquini; F. Almerigogna. Autoimmune hepatitis in a patient affected by neuromyelitis optica: A new association. Clinics and Research in Hepatology and Gastroenterology 2013, 38, e33 -e35.
AMA StyleR.G. Romanelli, F. Fassio, F. Cappelli, M.G. Giudizi, I. Cecioni, A. Matucci, F. Castiglione, R. Tarquini, F. Almerigogna. Autoimmune hepatitis in a patient affected by neuromyelitis optica: A new association. Clinics and Research in Hepatology and Gastroenterology. 2013; 38 (2):e33-e35.
Chicago/Turabian StyleR.G. Romanelli; F. Fassio; F. Cappelli; M.G. Giudizi; I. Cecioni; A. Matucci; F. Castiglione; R. Tarquini; F. Almerigogna. 2013. "Autoimmune hepatitis in a patient affected by neuromyelitis optica: A new association." Clinics and Research in Hepatology and Gastroenterology 38, no. 2: e33-e35.
Buckwheat allergy is considered a rare food allergy outside of Asia. In Europe, buckwheat has been described mainly as a hidden allergen. Data on the prevalence of buckwheat hypersensitivity in non-Asian countries is very poor. The aim of this multicenter study was to evaluate the prevalence of buckwheat sensitization and its association with other sensitizations among patients referred to allergy clinics in different geographic areas of Italy. All patients referred to 18 Italian allergy clinics from February through April 2011 were included in the study and evaluated for sensitization to buckwheat and other allergens depending on their clinical history. A total of 1,954 patients were included in the study and 61.3% of them were atopic. Mean prevalence of buckwheat sensitization was 3.6% with significant difference between Northern (4.5%), Central (2.2%) and Southern (2.8%) regions. This is, to our knowledge, the largest epidemiological survey on buckwheat allergy reported outside of Asia. Buckwheat is an emerging allergen in Italy, being more frequently associated to sensitization in Northern regions.
I. Badiu; E. Olivieri; M. Montagni; G. Guida; S. Mietta; S. Pizzimenti; Marco Caminati; M.R. Yacoub; Enrico Tombetti; D. Preziosi; C. Quecchia; S. Minetti; S. Facchetti; F. Fassio; I. Massaro; L. Corradi; M.C. Turi; A. Colagiovanni; L. Pascolini; F.W. Rossi; L. Losappio; L. Sansone; S. Imbesi; S. Leto Barone; G. Mistrello; Enrico Heffler. Italian Study on Buckwheat Allergy: Prevalence and Clinical Features of Buckwheat-Sensitized Patients in Italy. International Journal of Immunopathology and Pharmacology 2013, 26, 801 -806.
AMA StyleI. Badiu, E. Olivieri, M. Montagni, G. Guida, S. Mietta, S. Pizzimenti, Marco Caminati, M.R. Yacoub, Enrico Tombetti, D. Preziosi, C. Quecchia, S. Minetti, S. Facchetti, F. Fassio, I. Massaro, L. Corradi, M.C. Turi, A. Colagiovanni, L. Pascolini, F.W. Rossi, L. Losappio, L. Sansone, S. Imbesi, S. Leto Barone, G. Mistrello, Enrico Heffler. Italian Study on Buckwheat Allergy: Prevalence and Clinical Features of Buckwheat-Sensitized Patients in Italy. International Journal of Immunopathology and Pharmacology. 2013; 26 (3):801-806.
Chicago/Turabian StyleI. Badiu; E. Olivieri; M. Montagni; G. Guida; S. Mietta; S. Pizzimenti; Marco Caminati; M.R. Yacoub; Enrico Tombetti; D. Preziosi; C. Quecchia; S. Minetti; S. Facchetti; F. Fassio; I. Massaro; L. Corradi; M.C. Turi; A. Colagiovanni; L. Pascolini; F.W. Rossi; L. Losappio; L. Sansone; S. Imbesi; S. Leto Barone; G. Mistrello; Enrico Heffler. 2013. "Italian Study on Buckwheat Allergy: Prevalence and Clinical Features of Buckwheat-Sensitized Patients in Italy." International Journal of Immunopathology and Pharmacology 26, no. 3: 801-806.
Dear Editor, We would like to thank Dr. Correale and Colleagues for letting us gain further insight in the similarities and differences between Tako-Tsubo cardiomyopathy (TTC) and Kounis syndrome (KS). We recently reviewed KS in this Journal [1], focusing on how it is differently dealt in allergologic and cardiologic literature. Dr. Correale and Colleagues reported an interesting case of TTC during an asthma attack, which was presumably due to cephalosporin allergy [2]. They wonder whether there might be a link between TTC during an allergic reaction and KS (also named allergic acute coronary syndrome) [3]. The question is absolutely relevant, as several cases of TTC have been reported during or immediately after severe allergic reactions [4]. In the case reported by Correale et al. [2], we have to note that the allergic trigger has been postulated on a clinical basis, as total serum IgE elevation is an absolutely unspecific marker for drug allergy and no specific test for beta-lactam all
Filippo Fassio; Fabio Almerigogna. Tako-Tsubo cardiomyopathy or Kounis syndrome: finding differences and similarities to answer the question. Internal and Emergency Medicine 2013, 8, 637 -638.
AMA StyleFilippo Fassio, Fabio Almerigogna. Tako-Tsubo cardiomyopathy or Kounis syndrome: finding differences and similarities to answer the question. Internal and Emergency Medicine. 2013; 8 (7):637-638.
Chicago/Turabian StyleFilippo Fassio; Fabio Almerigogna. 2013. "Tako-Tsubo cardiomyopathy or Kounis syndrome: finding differences and similarities to answer the question." Internal and Emergency Medicine 8, no. 7: 637-638.
The clinical picture of myocardial ischemia accompanying allergic reactions is defined in the cardiologic literature as Kounis syndrome (KS) or allergic angina/myocardial infarction. In PubMed, a search for “Kounis syndrome”, “allergic angina” or “allergic myocardial infarction” retrieves more than 100 results (among case reports, case series and reviews), most of which are published in cardiology/internal medicine/emergency medicine journals. In allergologic literature, heart involvement during anaphylactic reactions is well documented, but Kounis syndrome is hardly mentioned. Single case reports and small case series of angina triggered by allergic reactions have been reported for many years, and involvement of histamine and others mast cell mediators in the pathogenesis of coronary spasm has long been hypothesized, but the existence of an allergic acute coronary syndrome (ACS) is still questioned in the allergologic scientific community. Putative mechanisms of an allergic acute coronary syndrome include coronary spasm or heart tissue-resident mast cell activation (precipitating coronary spasm or inducing plaque rupture and coronary or stent thrombosis) due to systemic increase of allergic mediators, or heart tissue-resident mast cell activation by local stimuli. Indeed, the pathogenic mechanism of an ACS after an allergic insult might be related to direct effects of mast cell mediators on the myocardium and the atherosclerotic plaque, or to exacerbation of preexisting disease by the hemodynamic stress of the acute allergic/anaphylactic reaction. Which of these mechanisms is most important is still unclear, and this review outlines current views in the cardiologic and allergologic literature.
Filippo Fassio; Fabio Almerigogna. Kounis syndrome (allergic acute coronary syndrome): different views in allergologic and cardiologic literature. Internal and Emergency Medicine 2012, 7, 489 -495.
AMA StyleFilippo Fassio, Fabio Almerigogna. Kounis syndrome (allergic acute coronary syndrome): different views in allergologic and cardiologic literature. Internal and Emergency Medicine. 2012; 7 (6):489-495.
Chicago/Turabian StyleFilippo Fassio; Fabio Almerigogna. 2012. "Kounis syndrome (allergic acute coronary syndrome): different views in allergologic and cardiologic literature." Internal and Emergency Medicine 7, no. 6: 489-495.
In less than half a century, allergy, originally perceived as a rare disease, has become a major public health threat, today affecting the lives of more than 60 million people in Europe, and probably close to one billion worldwide, thereby heavily impacting the budgets of public health systems. More disturbingly, its prevalence and impact are on the rise, a development that has been associated with environmental and lifestyle changes accompanying the continuous process of urbanization and globalization. Therefore, there is an urgent need to prioritize and concert research efforts in the field of allergy, in order to achieve sustainable results on prevention, diagnosis and treatment of this most prevalent chronic disease of the 21st century. The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization in the field of allergy, promoting excellence in clinical care, education, training and basic and translational research, all with the ultimate goal of improving the health of allergic patients. The European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is a non-profit network of allergy, asthma and Chronic Obstructive Pulmonary Disorder (COPD) patients’ organizations. In support of their missions, the present EAACI Position Paper, in collaboration with EFA, highlights the most important research needs in the field of allergy to serve as key recommendations for future research funding at the national and European levels. Although allergies may involve almost every organ of the body and an array of diverse external factors act as triggers, there are several common themes that need to be prioritized in research efforts. As in many other chronic diseases, effective prevention, curative treatment and accurate, rapid diagnosis represent major unmet needs. Detailed phenotyping/endotyping stands out as widely required in order to arrange or re-categorize clinical syndromes into more coherent, uniform and treatment-responsive groups. Research efforts to unveil the basic pathophysiologic pathways and mechanisms, thus leading to the comprehension and resolution of the pathophysiologic complexity of allergies will allow for the design of novel patient-oriented diagnostic and treatment protocols. Several allergic diseases require well-controlled epidemiological description and surveillance, using disease registries, pharmacoeconomic evaluation, as well as large biobanks. Additionally, there is a need for extensive studies to bring promising new biotechnological innovations, such as biological agents, vaccines of modified allergen molecules and engineered components for allergy diagnosis, closer to clinical practice. Finally, particular attention should be paid to the difficult-to-manage, precarious and costly severe disease forms and/or exacerbations. Nonetheless, currently arising treatments, mainly in the fields of immunotherapy and biologicals, hold great promise for targeted and causal management of allergic conditions. Active involvement of all stakeholders, including Patient Organizations and policy makers are necessary to achieve the aims emphasized herein.
Nikolaos G Papadopoulos; Ioana Agache; Sevim Bavbek; Beatrice M Bilo; Fulvio Braido; Victoria Cardona; Adnan Custovic; Jan Demonchy; Pascal Demoly; Philippe Eigenmann; Jacques Gayraud; Clive Grattan; Enrico Heffler; Peter W Hellings; Marek Jutel; Edward Knol; Jan Lötvall; Antonella Muraro; Lars K Poulsen; Graham Roberts; Peter Schmid‐Grendelmeier; Chrysanthi Skevaki; Massimo Triggiani; Ronald Vanree; Thomas Werfel; Breda Flood; Susanna Palkonen; Roberta Savli; Pia Allegri; Isabella Annesi‐Maesano; Francesco Annunziato; Dario Antolin‐Amerigo; Christian Apfelbacher; Miguel Blanca; Ewa Bogacka; Patrizia Bonadonna; Matteo Bonini; Onur Boyman; Knut Brockow; Peter Burney; Jeroen Buters; Indre Butiene; Moises Calderon; Lars Olaf Cardell; Jean‐Christoph Caubet; Sevcan Celenk; Ewa Cichocka‐Jarosz; Cemal Cingi; Mariana Couto; Nicolette Dejong; Stefano Del Giacco; Nikolaos Douladiris; Filippo Fassio; Jean‐Luc Fauquert; Javier Fernandez; Montserrat Fernandez Rivas; Marta Ferrer; Carsten Flohr; James Gardner; Jon Genuneit; Philippe Gevaert; Anna Groblewska; Eckard Hamelmann; Hans Jürgen Hoffmann; Karin Hoffmann‐Sommergruber; Lilit Hovhannisyan; Valérie Hox; Frode L Jahnsen; Ömer Kalayci; Ayse Füsun Kalpaklioglu; Jörg Kleine‐Tebbe; George Konstantinou; Marcin Kurowski; Susanne Lau; Roger Lauener; Antti Lauerma; Kirsty Logan; Antoine Magnan; Joanna Makowska; Heidi Makrinioti; Paraskevi Mangina; Felicia Manole; Adriano Mari; Angel Mazon; Clare Mills; Ervinç Mingomataj; Bodo Niggemann; Gunnar Nilsson; Markus Ollert; Liam O'Mahony; Serena O'Neil; Gianni Pala; Alberto Papi; Gianni Passalacqua; Michael Perkin; Oliver Pfaar; Constantinos Pitsios; Santiago Quirce; Ulrike Raap; Monika Raulf‐Heimsoth; Claudio Rhyner; Paula Robson‐Ansley; Rodrigo Rodrigues Alves; Zeljka Roje; Carmen Rondon; Odilija Rudzeviciene; Franziska Ruëff; Maia Rukhadze; Gabriele Rumi; Cansin Sackesen; Alexandra F Santos; Annalisa Santucci; Christian Scharf; Carsten Schmidt‐Weber; Benno Schnyder; Jürgen Schwarze; Gianenrico Senna; Svetlana Sergejeva; Sven Seys; Andrea Siracusa; Isabel Skypala; Milena Sokolowska; Francois Spertini; Radoslaw Spiewak; Aline Sprikkelman; Gunter Sturm; Ines Swoboda; Ingrid Terreehorst; Elina Toskala; Claudia Traidl‐Hoffmann; Carina Venter; Berber Vlieg‐Boerstra; Paul Whitacker; Margitta Worm; Paraskevi Xepapadaki; Cezmi A Akdis. Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clinical and Translational Allergy 2012, 2, 21 -21.
AMA StyleNikolaos G Papadopoulos, Ioana Agache, Sevim Bavbek, Beatrice M Bilo, Fulvio Braido, Victoria Cardona, Adnan Custovic, Jan Demonchy, Pascal Demoly, Philippe Eigenmann, Jacques Gayraud, Clive Grattan, Enrico Heffler, Peter W Hellings, Marek Jutel, Edward Knol, Jan Lötvall, Antonella Muraro, Lars K Poulsen, Graham Roberts, Peter Schmid‐Grendelmeier, Chrysanthi Skevaki, Massimo Triggiani, Ronald Vanree, Thomas Werfel, Breda Flood, Susanna Palkonen, Roberta Savli, Pia Allegri, Isabella Annesi‐Maesano, Francesco Annunziato, Dario Antolin‐Amerigo, Christian Apfelbacher, Miguel Blanca, Ewa Bogacka, Patrizia Bonadonna, Matteo Bonini, Onur Boyman, Knut Brockow, Peter Burney, Jeroen Buters, Indre Butiene, Moises Calderon, Lars Olaf Cardell, Jean‐Christoph Caubet, Sevcan Celenk, Ewa Cichocka‐Jarosz, Cemal Cingi, Mariana Couto, Nicolette Dejong, Stefano Del Giacco, Nikolaos Douladiris, Filippo Fassio, Jean‐Luc Fauquert, Javier Fernandez, Montserrat Fernandez Rivas, Marta Ferrer, Carsten Flohr, James Gardner, Jon Genuneit, Philippe Gevaert, Anna Groblewska, Eckard Hamelmann, Hans Jürgen Hoffmann, Karin Hoffmann‐Sommergruber, Lilit Hovhannisyan, Valérie Hox, Frode L Jahnsen, Ömer Kalayci, Ayse Füsun Kalpaklioglu, Jörg Kleine‐Tebbe, George Konstantinou, Marcin Kurowski, Susanne Lau, Roger Lauener, Antti Lauerma, Kirsty Logan, Antoine Magnan, Joanna Makowska, Heidi Makrinioti, Paraskevi Mangina, Felicia Manole, Adriano Mari, Angel Mazon, Clare Mills, Ervinç Mingomataj, Bodo Niggemann, Gunnar Nilsson, Markus Ollert, Liam O'Mahony, Serena O'Neil, Gianni Pala, Alberto Papi, Gianni Passalacqua, Michael Perkin, Oliver Pfaar, Constantinos Pitsios, Santiago Quirce, Ulrike Raap, Monika Raulf‐Heimsoth, Claudio Rhyner, Paula Robson‐Ansley, Rodrigo Rodrigues Alves, Zeljka Roje, Carmen Rondon, Odilija Rudzeviciene, Franziska Ruëff, Maia Rukhadze, Gabriele Rumi, Cansin Sackesen, Alexandra F Santos, Annalisa Santucci, Christian Scharf, Carsten Schmidt‐Weber, Benno Schnyder, Jürgen Schwarze, Gianenrico Senna, Svetlana Sergejeva, Sven Seys, Andrea Siracusa, Isabel Skypala, Milena Sokolowska, Francois Spertini, Radoslaw Spiewak, Aline Sprikkelman, Gunter Sturm, Ines Swoboda, Ingrid Terreehorst, Elina Toskala, Claudia Traidl‐Hoffmann, Carina Venter, Berber Vlieg‐Boerstra, Paul Whitacker, Margitta Worm, Paraskevi Xepapadaki, Cezmi A Akdis. Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clinical and Translational Allergy. 2012; 2 (1):21-21.
Chicago/Turabian StyleNikolaos G Papadopoulos; Ioana Agache; Sevim Bavbek; Beatrice M Bilo; Fulvio Braido; Victoria Cardona; Adnan Custovic; Jan Demonchy; Pascal Demoly; Philippe Eigenmann; Jacques Gayraud; Clive Grattan; Enrico Heffler; Peter W Hellings; Marek Jutel; Edward Knol; Jan Lötvall; Antonella Muraro; Lars K Poulsen; Graham Roberts; Peter Schmid‐Grendelmeier; Chrysanthi Skevaki; Massimo Triggiani; Ronald Vanree; Thomas Werfel; Breda Flood; Susanna Palkonen; Roberta Savli; Pia Allegri; Isabella Annesi‐Maesano; Francesco Annunziato; Dario Antolin‐Amerigo; Christian Apfelbacher; Miguel Blanca; Ewa Bogacka; Patrizia Bonadonna; Matteo Bonini; Onur Boyman; Knut Brockow; Peter Burney; Jeroen Buters; Indre Butiene; Moises Calderon; Lars Olaf Cardell; Jean‐Christoph Caubet; Sevcan Celenk; Ewa Cichocka‐Jarosz; Cemal Cingi; Mariana Couto; Nicolette Dejong; Stefano Del Giacco; Nikolaos Douladiris; Filippo Fassio; Jean‐Luc Fauquert; Javier Fernandez; Montserrat Fernandez Rivas; Marta Ferrer; Carsten Flohr; James Gardner; Jon Genuneit; Philippe Gevaert; Anna Groblewska; Eckard Hamelmann; Hans Jürgen Hoffmann; Karin Hoffmann‐Sommergruber; Lilit Hovhannisyan; Valérie Hox; Frode L Jahnsen; Ömer Kalayci; Ayse Füsun Kalpaklioglu; Jörg Kleine‐Tebbe; George Konstantinou; Marcin Kurowski; Susanne Lau; Roger Lauener; Antti Lauerma; Kirsty Logan; Antoine Magnan; Joanna Makowska; Heidi Makrinioti; Paraskevi Mangina; Felicia Manole; Adriano Mari; Angel Mazon; Clare Mills; Ervinç Mingomataj; Bodo Niggemann; Gunnar Nilsson; Markus Ollert; Liam O'Mahony; Serena O'Neil; Gianni Pala; Alberto Papi; Gianni Passalacqua; Michael Perkin; Oliver Pfaar; Constantinos Pitsios; Santiago Quirce; Ulrike Raap; Monika Raulf‐Heimsoth; Claudio Rhyner; Paula Robson‐Ansley; Rodrigo Rodrigues Alves; Zeljka Roje; Carmen Rondon; Odilija Rudzeviciene; Franziska Ruëff; Maia Rukhadze; Gabriele Rumi; Cansin Sackesen; Alexandra F Santos; Annalisa Santucci; Christian Scharf; Carsten Schmidt‐Weber; Benno Schnyder; Jürgen Schwarze; Gianenrico Senna; Svetlana Sergejeva; Sven Seys; Andrea Siracusa; Isabel Skypala; Milena Sokolowska; Francois Spertini; Radoslaw Spiewak; Aline Sprikkelman; Gunter Sturm; Ines Swoboda; Ingrid Terreehorst; Elina Toskala; Claudia Traidl‐Hoffmann; Carina Venter; Berber Vlieg‐Boerstra; Paul Whitacker; Margitta Worm; Paraskevi Xepapadaki; Cezmi A Akdis. 2012. "Research needs in allergy: an EAACI position paper, in collaboration with EFA." Clinical and Translational Allergy 2, no. 1: 21-21.
This year is the 10th anniversary of the European Academy of Allergy and Clinical Immunology (EAACI) Junior Members and Affiliates (JMAs). The aim of this review is to highlight the work and activities of EAACI JMAs. To this end, we have summarized all the initiatives taken by JMAs during the last 10 yr. EAACI JMAs are currently a group of over 2380 clinicians and scientists under the age of 35 yr, who support the continuous education of the Academy's younger members. For the past decade, JMAs enjoy a steadily increasing number of benefits such as free online access to the Academy's journals, the possibility to apply for Fellowships and the Mentorship Program, travel grants to attend scientific meetings, and many more. In addition, JMAs have been involved in task forces, cooperation schemes with other scientific bodies, organization of JMA focused sessions during EAACI meetings, and participation in the activities of EAACI communication platforms. EAACI JMA activities represent an ideal example of recruiting, training, and educating young scientists in order for them to thrive as future experts in their field. This model may serve as a prototype for other scientific communities, several of which have already adapted similar policies.
Chrysanthi L. Skevaki; Paraskevi Maggina; Alexandra Santos; Rodrigo Rodrigues-Alves; Dario Antolin-Amerigo; Luis Miguel Borrego; Isabell Bretschneider; Indre Butiene; Mariana Couto; Filippo Fassio; James Gardner; Maria Xatzipsalti; Lilit Hovhannisyan; Valerie Hox; Heidi Makrinioti; Serena E. O′neil; Gianni Pala; Michael Rudenko; Annalisa Santucci; Sven Seys; Milena Sokolowska; Paul Whitaker; Enrico Heffler. The 10th anniversary of the Junior Members and Affiliates of the European Academy of Allergy and Clinical Immunology. Pediatric Allergy and Immunology 2011, 22, 754 -757.
AMA StyleChrysanthi L. Skevaki, Paraskevi Maggina, Alexandra Santos, Rodrigo Rodrigues-Alves, Dario Antolin-Amerigo, Luis Miguel Borrego, Isabell Bretschneider, Indre Butiene, Mariana Couto, Filippo Fassio, James Gardner, Maria Xatzipsalti, Lilit Hovhannisyan, Valerie Hox, Heidi Makrinioti, Serena E. O′neil, Gianni Pala, Michael Rudenko, Annalisa Santucci, Sven Seys, Milena Sokolowska, Paul Whitaker, Enrico Heffler. The 10th anniversary of the Junior Members and Affiliates of the European Academy of Allergy and Clinical Immunology. Pediatric Allergy and Immunology. 2011; 22 (8):754-757.
Chicago/Turabian StyleChrysanthi L. Skevaki; Paraskevi Maggina; Alexandra Santos; Rodrigo Rodrigues-Alves; Dario Antolin-Amerigo; Luis Miguel Borrego; Isabell Bretschneider; Indre Butiene; Mariana Couto; Filippo Fassio; James Gardner; Maria Xatzipsalti; Lilit Hovhannisyan; Valerie Hox; Heidi Makrinioti; Serena E. O′neil; Gianni Pala; Michael Rudenko; Annalisa Santucci; Sven Seys; Milena Sokolowska; Paul Whitaker; Enrico Heffler. 2011. "The 10th anniversary of the Junior Members and Affiliates of the European Academy of Allergy and Clinical Immunology." Pediatric Allergy and Immunology 22, no. 8: 754-757.
Natural killer (NK) cells play a fundamental role in innate and early phases of adaptive immunity against viral infections, both in humans and in animal models. To date, NK cell deficiencies in patients with severe herpetic infections have been reported in single cases, and their role as predisposing factor is still controversial. Five children affected by herpetic encephalitis were consecutively admitted to the Anna Meyer Children's Hospital in Florence (Italy) between 2003 and 2005. We therefore investigated the presence of NK cell deficiencies in a consecutive series of children with herpetic encephalitis. Five healthy children were included in the study as controls. Differential WBC counts, main Ig and IgE class serum analysis, cytofluorimetric analysis of circulating T, B and NK cells were performed on our study population. Sequencing of a selected region of CD16A gene transcript was carried out in two patients. All patients resulted to be affected by deficiencies related to NK cells in respect to controls. One patient was also affected by lymphopenia, while no other significant deficits of immunity were detected in the study population. To date, this is the first survey that demonstrates isolated NK cell deficiencies in a cohort of consecutive patients affected by severe herpes simplex infections. These findings suggest a role for NK cell deficiencies as a predisposing factor for increased susceptibility and severe course of disease in these patients.
F. Almerigogna; F. Fassio; M.G. Giudizi; R. Biagiotti; C. Manuelli; Elena Chiappini; L. Galli; S. Romagnani; M. De Martino. Natural Killer Cell Deficiencies in a Consecutive Series of Children with Herpetic Encephalitis. International Journal of Immunopathology and Pharmacology 2011, 24, 231 -238.
AMA StyleF. Almerigogna, F. Fassio, M.G. Giudizi, R. Biagiotti, C. Manuelli, Elena Chiappini, L. Galli, S. Romagnani, M. De Martino. Natural Killer Cell Deficiencies in a Consecutive Series of Children with Herpetic Encephalitis. International Journal of Immunopathology and Pharmacology. 2011; 24 (1):231-238.
Chicago/Turabian StyleF. Almerigogna; F. Fassio; M.G. Giudizi; R. Biagiotti; C. Manuelli; Elena Chiappini; L. Galli; S. Romagnani; M. De Martino. 2011. "Natural Killer Cell Deficiencies in a Consecutive Series of Children with Herpetic Encephalitis." International Journal of Immunopathology and Pharmacology 24, no. 1: 231-238.